Polaris Partners

Delphia Therapeutics operates and manages a laboratory that develops treatments for cancer cells. It studies cancer-driving pathways and their effect on creating cancer medicines. Delphia Therapeutics is based in Boston, USA.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Contact Networks is a Boston-based company that specializes in Enterprise Relationship Management (ERM) software solutions designed to assist professional services firms in maximizing their relationship networks to drive new business opportunities. The company's flagship product, ContactNet, is an automated search application that quickly identifies employees with the strongest relationships to potential clients or prospects. This service helps organizations uncover existing professional connections, allowing for more effective client engagement. By providing an easy-to-use platform that integrates with existing IT and CRM systems, Contact Networks enhances the ability of firms to leverage their internal networks for business development. The company was acquired by Thomson Reuters in 2007.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on developing solutions to mitigate healthcare cyber incidents related to patient data theft, specifically targeting the needs of chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patients’ protected health information (PHI). By adopting a proactive risk management approach, the platform aims to improve patient care, clinician satisfaction, regulatory compliance, and innovation rates, ultimately helping healthcare organizations assess and reduce the risks associated with data breaches.

Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

OM1, Inc. is a digital health company that specializes in developing a platform for healthcare organizations to measure and forecast patient outcomes. The platform is designed to assist hospitals, health systems, and other healthcare providers in meeting various patient reported and clinical outcomes requirements for value-based care programs. By leveraging advanced predictive and prescriptive analytics, OM1 aims to mitigate risks, lower costs, and enhance the understanding of treatment outcomes across the care continuum. The company's technology gathers and synthesizes clinical data to provide AI-driven insights, enabling healthcare organizations to analyze and utilize outcomes data effectively. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on developing solutions to mitigate healthcare cyber incidents related to patient data theft, specifically targeting the needs of chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patients’ protected health information (PHI). By adopting a proactive risk management approach, the platform aims to improve patient care, clinician satisfaction, regulatory compliance, and innovation rates, ultimately helping healthcare organizations assess and reduce the risks associated with data breaches.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Amagma Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2019. The company focuses on the discovery and development of antibody therapeutics aimed at treating inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma targets overactive extracellular proteases that lead to tissue damage and contribute to widespread inflammatory responses. By addressing these mechanisms, the company aims to provide effective and safe therapeutic options for clinicians dealing with such conditions.

1366 Technologies is a manufacturer of silicon wafers used to deliver solar modules. The company's silicon wafers leverage existing billion-dollar cell and module investments, enabling businesses to get a long-term, differentiated product roadmap. It was founded in 2008 and is headquartered in Bedford, Massachusetts.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company specializes in soluble guanylate cyclase (sGC) pharmacology to realize the therapeutic potential of next-generation sGC stimulators. Its product pipeline includes Olinciguat, an oral sGC stimulator currently in Phase II trials for sickle cell disease; Praliciguat, also an oral sGC stimulator in Phase II for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, which is in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is engaged in the discovery of liver-targeted and lung-targeted sGC stimulators. Founded in 2018, the company is headquartered in Cambridge, Massachusetts.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Drizly is an online marketplace specializing in the delivery of alcoholic beverages, including beer, wine, and spirits. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly operates in 235 markets, providing consumers of legal drinking age with a convenient and personalized shopping experience. The platform offers a diverse selection of products, allowing customers to order not only alcoholic drinks but also accompanying items like mixers and garnishes, all from the comfort of their homes. By partnering with local retailers, Drizly helps these businesses expand their reach and gain valuable market insights, ultimately aiding them in increasing sales and diversifying their offerings.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

OM1, Inc. is a digital health company that specializes in developing a platform for healthcare organizations to measure and forecast patient outcomes. The platform is designed to assist hospitals, health systems, and other healthcare providers in meeting various patient reported and clinical outcomes requirements for value-based care programs. By leveraging advanced predictive and prescriptive analytics, OM1 aims to mitigate risks, lower costs, and enhance the understanding of treatment outcomes across the care continuum. The company's technology gathers and synthesizes clinical data to provide AI-driven insights, enabling healthcare organizations to analyze and utilize outcomes data effectively. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Qstream, Inc. is a software as a service company that offers a mobile sales acceleration platform designed to enhance job proficiency and drive behavioral change within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves various industries, including technology, financial services, and life sciences. The company specializes in micro-learning and analytics, aiming to improve the effectiveness of sales personnel through measurable outcomes. Qstream also has engineering facilities in Dublin, Ireland, and Hood River, Oregon, along with sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Boxever Ltd. is a customer intelligence service provider specializing in the travel industry, founded in 2010 and headquartered in Dublin, Ireland, with an additional office in Boston. The company leverages data and artificial intelligence to help travel companies enhance customer relationships by integrating both online and offline customer data. Boxever's platform includes several key solutions: BOXEVER TX, which visualizes the customer journey; TX-CORE, a traveler experience management platform that anticipates customer needs; and TX-NOW, an offer management platform. The company collaborates with major brands, including Emirates and Ryanair, to deliver personalized customer experiences and optimize every interaction. Recognized for its innovative use of AI, Boxever has been acknowledged as a leading player in personalization within the industry.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, it is focused on discovering and developing innovative genome editing therapeutics to address a wide range of serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 technology, which employs a protein-RNA complex to target and modify specific DNA sequences for therapeutic purposes. Editas Medicine aims to translate its advanced genome editing technologies into human therapeutics that can provide precise and corrective molecular modifications to treat genetic disorders. With a strong foundation of patent filings and intellectual property, the company is positioned to advance its early findings into viable treatments for various diseases at the genetic level.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Established in 2011 and based in Waltham, Massachusetts, the company is engaged in creating pharmaceutical preparations aimed at diagnosing and treating oncological, tumor, and inflammatory diseases. XTuit Pharmaceuticals employs novel strategies to enhance cancer therapy by specifically addressing the tumor microenvironment. Its drug development pipeline includes innovative approaches that inhibit extracellular matrix synthesis and stabilize activated stromal cells, utilizing a clinical biomarker platform for effective treatment outcomes.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Drizly is an online marketplace specializing in the delivery of alcoholic beverages, including beer, wine, and spirits. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly operates in 235 markets, providing consumers of legal drinking age with a convenient and personalized shopping experience. The platform offers a diverse selection of products, allowing customers to order not only alcoholic drinks but also accompanying items like mixers and garnishes, all from the comfort of their homes. By partnering with local retailers, Drizly helps these businesses expand their reach and gain valuable market insights, ultimately aiding them in increasing sales and diversifying their offerings.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Boxever Ltd. is a customer intelligence service provider specializing in the travel industry, founded in 2010 and headquartered in Dublin, Ireland, with an additional office in Boston. The company leverages data and artificial intelligence to help travel companies enhance customer relationships by integrating both online and offline customer data. Boxever's platform includes several key solutions: BOXEVER TX, which visualizes the customer journey; TX-CORE, a traveler experience management platform that anticipates customer needs; and TX-NOW, an offer management platform. The company collaborates with major brands, including Emirates and Ryanair, to deliver personalized customer experiences and optimize every interaction. Recognized for its innovative use of AI, Boxever has been acknowledged as a leading player in personalization within the industry.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

1366 Technologies is a manufacturer of silicon wafers used to deliver solar modules. The company's silicon wafers leverage existing billion-dollar cell and module investments, enabling businesses to get a long-term, differentiated product roadmap. It was founded in 2008 and is headquartered in Bedford, Massachusetts.

aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Each time you share a digital document, the minute you've sent it, you are no longer in control. docTrackr helps businesses keep their documents under control, wherever they're stored, whomever they're shared with - i.e. you can remotely destroy them, update them and know what people are doing with them in real-time. doctrackr's technology was designed to protect the most sensitive documents in business. docTrackr provides advanced document intelligence and control, giving enterprises complete visibility into document usage. With docTrackr, managers can control permissions, track usage, and even destroy documents remotely. All through all through an easy to use dashboard. They are complementary to document management platforms such as Dropbox, Box.net or Google Drive. docTrackr continues to provide a benefit to their users even once the documents are extracted from their platform and redistributed. docTrackr was part of TechStars – #1 startup accelerator in the world – and is based in the USA (Boston – MA) and in Europe (Paris – France; Bucharest – Romania), and backed by Polaris Ventures and Atlas Ventures. It was acquired by Intralinks.com for $10 million dollars cash.

WikiCell Designs Inc., a Cambridge, Mass. and Paris, France-based company developing edible forms of food and beverage packaging.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Follica, Inc. is focused on developing innovative therapies for hair loss, targeting the hair follicle, which is crucial for the growth and replenishment of hair and skin. The company offers a proprietary in-office treatment device that disrupts the skin to stimulate the creation of new hair follicles, alongside an at-home treatment system that delivers therapeutic compounds directly to the scalp on a daily basis. Follica aims to address the significant market for hair follicle treatments, which exceeds $10 billion annually, by providing effective solutions in an area lacking truly successful options. Founded in 2005 and based in Boston, Massachusetts, Follica operates as a subsidiary of PureTech Health plc.

aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.

SiOnyx, Inc. is a company based in Beverly, Massachusetts, specializing in the development and commercialization of advanced semiconductor processes that improve the infrared sensitivity of silicon-based photonics. Established in 2005, SiOnyx focuses on creating high-performance light sensing devices suitable for a variety of applications, including security, defense, consumer electronics, industrial use, medical technology, and automotive sectors. The company is recognized for its innovative XQE CMOS image sensors, which enable capabilities such as night vision, biometrics, eye-tracking, and natural human interfaces. Additionally, SiOnyx produces HD action video cameras that utilize its ultra-low-light image sensor technology, making digital night vision more accessible across various industries.

1366 Technologies is a manufacturer of silicon wafers used to deliver solar modules. The company's silicon wafers leverage existing billion-dollar cell and module investments, enabling businesses to get a long-term, differentiated product roadmap. It was founded in 2008 and is headquartered in Bedford, Massachusetts.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Follica, Inc. is focused on developing innovative therapies for hair loss, targeting the hair follicle, which is crucial for the growth and replenishment of hair and skin. The company offers a proprietary in-office treatment device that disrupts the skin to stimulate the creation of new hair follicles, alongside an at-home treatment system that delivers therapeutic compounds directly to the scalp on a daily basis. Follica aims to address the significant market for hair follicle treatments, which exceeds $10 billion annually, by providing effective solutions in an area lacking truly successful options. Founded in 2005 and based in Boston, Massachusetts, Follica operates as a subsidiary of PureTech Health plc.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.